Suzanne E. Wardell

4.9k total citations · 2 hit papers
50 papers, 3.4k citations indexed

About

Suzanne E. Wardell is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Suzanne E. Wardell has authored 50 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Genetics, 19 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Suzanne E. Wardell's work include Estrogen and related hormone effects (24 papers), HER2/EGFR in Cancer Research (9 papers) and Advanced Breast Cancer Therapies (9 papers). Suzanne E. Wardell is often cited by papers focused on Estrogen and related hormone effects (24 papers), HER2/EGFR in Cancer Research (9 papers) and Advanced Breast Cancer Therapies (9 papers). Suzanne E. Wardell collaborates with scholars based in United States, Australia and United Kingdom. Suzanne E. Wardell's co-authors include Donald P. McDonnell, Erik R. Nelson, John D. Norris, Jeff S. Jasper, Patrick M. Sullivan, Sung Hee Park, Christina Chao, Dean P. Edwards, Joseph Geradts and Michihisa Umetani and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Suzanne E. Wardell

49 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology

2013 632 citations Erik R. Nelson, Suzanne E. Wardell et al. Science profile →
The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells

2017 298 citations Suzanne E. Wardell, Ching‐yi Chang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Suzanne E. Wardell United States	28	1.6k	1.0k	1.0k	930	670	50	3.4k
Ching‐yi Chang United States	37	2.5k 1.5×	1.8k 1.8×	1.2k 1.2×	785 0.8×	710 1.1×	69	4.8k
Shin‐ichi Hayashi Japan	37	3.0k 1.8×	1.3k 1.3×	848 0.8×	1.4k 1.5×	538 0.8×	91	4.9k
Yoko Omoto Japan	29	1.1k 0.7×	1.2k 1.1×	553 0.5×	870 0.9×	353 0.5×	49	2.5k
John R. Hawse United States	36	1.9k 1.1×	1.1k 1.1×	575 0.6×	823 0.9×	332 0.5×	113	3.3k
Jonna Frasor United States	33	2.2k 1.3×	1.9k 1.8×	814 0.8×	1.3k 1.4×	236 0.4×	71	4.1k
Stephen Hiscox United Kingdom	36	2.1k 1.3×	472 0.5×	629 0.6×	1.4k 1.6×	353 0.5×	93	3.8k
Shixia Huang United States	30	2.4k 1.4×	481 0.5×	651 0.6×	1.3k 1.4×	372 0.6×	70	3.7k
Louise R. Howe United States	28	2.5k 1.5×	959 0.9×	702 0.7×	1.1k 1.2×	212 0.3×	37	4.4k
Pierre‐Marie Martin France	34	1.3k 0.8×	420 0.4×	747 0.7×	796 0.9×	562 0.8×	99	3.4k
Sankar Addya United States	34	2.4k 1.5×	293 0.3×	1.4k 1.3×	1.1k 1.1×	361 0.5×	106	4.2k

Countries citing papers authored by Suzanne E. Wardell

Since Specialization

Citations

This map shows the geographic impact of Suzanne E. Wardell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne E. Wardell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne E. Wardell more than expected).

Fields of papers citing papers by Suzanne E. Wardell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne E. Wardell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne E. Wardell. The network helps show where Suzanne E. Wardell may publish in the future.

Co-authorship network of co-authors of Suzanne E. Wardell

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne E. Wardell. A scholar is included among the top collaborators of Suzanne E. Wardell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne E. Wardell. Suzanne E. Wardell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wardell, Suzanne E., et al.. (2024). PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State. Cancer Discovery. 15(3). 595–615.

Artham, Sandeep, Suzanne E. Wardell, Binita Chakraborty, et al.. (2024). Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth. Science Advances. 10(39). eadp2442–eadp2442. 7 indexed citations

Hoj, Jacob P., Peter Winter, Suzanne E. Wardell, et al.. (2023). ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1. Proceedings of the National Academy of Sciences. 120(16). e2210418120–e2210418120. 5 indexed citations

Joh, Daniel Y., Jacob T. Heggestad, Shengwei Zhang, et al.. (2021). Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates. npj Breast Cancer. 7(1). 85–85. 12 indexed citations

Park, Sunghee, Rachid Safi, Sandeep Artham, et al.. (2020). The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Molecular Cancer Therapeutics. 19(7). 1395–1405. 27 indexed citations

Wardell, Suzanne E., Robert Baldi, Christina Chao, et al.. (2020). G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment. 180(3). 635–646. 37 indexed citations

Wardell, Suzanne E., et al.. (2019). Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy. Breast Cancer Research and Treatment. 179(1). 67–77. 25 indexed citations

Stice, James P., Suzanne E. Wardell, John D. Norris, et al.. (2017). CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC. Molecular Cancer Research. 15(6). 660–669. 22 indexed citations

Liberti, Maria V., Ziwei Dai, Suzanne E. Wardell, et al.. (2017). A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product. Cell Metabolism. 26(4). 648–659.e8. 143 indexed citations

10.

Norris, John D., Stephanie J. Ellison, David B. Stagg, et al.. (2017). Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. Journal of Clinical Investigation. 127(6). 2326–2338. 38 indexed citations

11.

Tang, Xiaohu, Chien‐Kuang Cornelia Ding, Jianli Wu, et al.. (2016). Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling. Oncogene. 36(30). 4235–4242. 69 indexed citations

12.

Pollock, Julie A., Suzanne E. Wardell, A.A. Parent, et al.. (2016). Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. Nature Chemical Biology. 12(10). 795–801. 16 indexed citations

13.

Wardell, Suzanne E., Matthew J. Ellis, Holly M. Alley, et al.. (2015). Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer. Clinical Cancer Research. 21(22). 5121–5130. 115 indexed citations

14.

Wright, Tricia M., Suzanne E. Wardell, Jeff S. Jasper, et al.. (2014). Delineation of a FOXA1/ERα/AGR2 Regulatory Loop That Is Dysregulated in Endocrine Therapy–Resistant Breast Cancer. Molecular Cancer Research. 12(12). 1829–1839. 33 indexed citations

15.

Wardell, Suzanne E., Erik R. Nelson, Christina Chao, & Donald P. McDonnell. (2013). Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease. Clinical Cancer Research. 19(9). 2420–2431. 113 indexed citations

16.

Nelson, Erik R., Suzanne E. Wardell, Jeff S. Jasper, et al.. (2013). 27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology. Science. 342(6162). 1094–1098. 632 indexed citations breakdown →

17.

Lu, Nick Z., Suzanne E. Wardell, Kerry L. Burnstein, et al.. (2006). International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors. Pharmacological Reviews. 58(4). 782–797. 311 indexed citations

18.

Wardell, Suzanne E. & Dean P. Edwards. (2005). Mechanisms Controlling Agonist and Antagonist Potential of Selective Progesterone Receptor Modulators (SPRMs). Seminars in Reproductive Medicine. 23(1). 9–21. 28 indexed citations

19.

Ranson, Malcolm & Suzanne E. Wardell. (2004). Gefitinib, a novel, orally administered agent for the treatment of cancer. Journal of Clinical Pharmacy and Therapeutics. 29(2). 95–103. 59 indexed citations

20.

Edwards, Dean P., Suzanne E. Wardell, & Viroj Boonyaratanakornkit. (2002). Progesterone receptor interacting coregulatory proteins and cross talk with cell signaling pathways. The Journal of Steroid Biochemistry and Molecular Biology. 83(1-5). 173–186. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact